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Introduction. Chronic Renal Failure (CRF) patients are consid-
ered to show genomic instability and are associated with a high 
risk of both cardiovascular diseases and cancer. We explored DNA 
damage due to two dialysis treatments in 20 patients undergoing 
bicarbonate haemodialysis (BD), 20 undergoing haemodiafiltra-
tion (HDF) and 40 healthy subjects.
Methods. The cytokinesis-block micronucleus (MN) assay was per-
formed on peripheral blood lymphocytes to evaluate genetic damage. 
Results. A higher frequency of MN in the dialysis groups com-
pared with controls was found. The results do not show a rela-
tionship between genetic instability and the type, frequency and 
duration of haemodialysis. The average BD and HDF treatment 
time was respectively 3.8 ± 6.3 and 3.7 ± 3.9 yrs. CAT and scin-
tigraphy was independently correlated with high levels of MN.
Conclusions. Overall, the frequency of MN in CRF patients 
undergoing dialysis therapy was observed to be higher. Further 
studies need to be performed on a larger number of patients and 
for a longer period.
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Summary
Introduction
Chronic Renal Failure (CRF) is a progressive disease 
with loss of kidney function over time  [1]. The early 
stages of CRF (stages 2 and 3) are characterized by a 
decrease in the glomerular filtration rate (the best pa-
rameter for categorising kidney function) and are gen-
erally asymptomatic. Advanced stages of the disease (4 
and 5) are manifested by a severely decreased glomeru-
lar filtration rate accompanied by clinical complications 
(hypertension, anaemia, bone disease), requiring renal 
replacement therapy when end-stage renal disease is 
reached [2].
CRF patients, regardless of whether they are receiving 
dialysis, present a high risk of cardiovascular patholo-
gies and cancer (mainly cervical, bladder, thyroid, and 
renal cell carcinoma) [3-5], as well as elevated levels of 
genetic damage  [6, 7]. This extensive damage may be 
related to impairment of DNA repair. DNA lesions may 
induce mutations in tumour-suppressors and oncogenes 
that may lead to malignancies if mutagenicity is not mit-
igated by repair mechanisms [8].
Uraemia, microinflammation and oxidative stress  [free 
radicals, reactive oxygen species (ROS), etc] are the 
main mechanisms underlying this phenomenon [6].
Indeed, evidence indicates that end-stage renal disease 
is associated with oxidative stress, as a result of both 
increased production of oxidants and weaker antioxidant 
defences [9-11].
This situation is aggravated by a series of events induced 
by dialysis treatment. Continuous contact of peripheral 
blood with dialysis membranes promotes the activa-
tion of leukocytes that produce various inflammatory 
mediators (e.g. complement and platelet-activating fac-
tor) [12].
Renal Replacement Therapies (RRT) involve peritoneal 
(or intracorporeal) dialysis, which is a blood-filtering 
method that uses the peritoneum, the serous membrane 
that lines the abdominal wall, to allow exchanges be-
tween blood and dialysis fluid, and extracorporeal dialy-
sis or haemodialysis, in which blood circulates outside 
the body, using an artificial membrane in an external fil-
ter to remove waste products [13].
The types of dialysis treatment respond to different ther-
apeutic needs, specifically the type and size of toxic mol-
ecules to be removed. Diffusive and diffusive-convective 
techniques are both currently used [14]. The former in-
clude Acetate and Bicarbonate Dialysis (BD), while the 
latter include Haemodiafiltration (HDF), an innovative 
diffusive-convective blood purification treatment devel-
Micronucleus in dialysis patients
E179
oped from BD, consisting of a combination of Haemofil-
tration (HF) and conventional Haemodialysis (HD) [15]. 
HDF combines the advantages of the diffusive method 
of removing low molecular weight solutes with those of 
convective treatment, which removes substances with 
medium/high molecular weight [16, 17].
Several studies have found high levels of genetic dam-
age in patients with CRF suffering from uraemia and 
oxidative stress, detected by methods such as sister-
chromatid exchange, the comet test and micronucleus 
assays [8, 18, 19]. Indeed, both CRF and the long-term 
HD therapy used to treat it can cause genomic dam-
age, leading to single and double-strand breaks, alka-
li-labile sites and formation of micronuclei (MN), in 
addition to reduction of DNA repair capacity [18, 20].
MN are DNA-containing particles that occur during 
mitosis and result from unrepaired DNA double-strand 
breaks, leading to chromatin fragments or whole chro-
mosomes being distributed incorrectly. MN frequency 
is considered a good surrogate biomarker for detecting 
genetic damage and evaluating cancer risk [21, 22]. The 
MN assay is performed on human lymphocytes because 
they are excellent markers of exposure; they circulate 
for years or even decades through different organs and 
accumulate DNA damage during their lifespan [23-25].
The aim of the present study is to evaluate DNA dam-
age in CRF patients undergoing BD and HDF dialysis 
techniques compared with a control group, by evaluating 
MN frequency in peripheral blood lymphocytes (PBL). 
Methods
Subjects. The study was carried out on a total of 80 in-
dividuals including 40 CRF patients (20 undergoing BD 
and 20 undergoing HDF) and 40 healthy controls.
Patients aged less than 18 years, pregnant, with ma-
lignancies, with bacterial or viral infections, hepatic 
impairment, or undergoing treatment with anti-inflam-
matory agents, cytostatics or immunosuppressive drugs 
were excluded. Healthy volunteers who did not meet the 
exclusion criteria served as control subjects.
All participants in the study were recruited at the “I. 
Veris Delli Ponti” hospital in Scorrano from May 2013 
to December 2014 and completed a questionnaire re-
questing general details and information on smoking 
habits, alcohol intake, occupational exposure and risk 
factors for cancer. 
This study was approved by the local institutional Eth-
ics Committee and informed consent was obtained from 
each patient enrolled.
Lymphocyte Culture and Cytokinesis-Block Micro-
nucleus (CBMN) Cytome Assay. Blood samples were 
obtained for each subject by venipuncture using heparin-
ized vacutainers and sent directly to the Laboratory of 
Hygiene of University of Salento.
300 μl of blood sample was added to 4.7 ml of Karyotyp-
ing medium. At 44-h incubation, 100 μl of cytochalasin 
B was added to the culture to arrest cytokinesis.
After 28-h incubation, the cultures were harvested by cen-
trifugation at 2000 rpm for 4 min at 25°C and treated with a 
hypotonic solution (112 mg KCl/20 ml of deionized water) 
for 10 min. The supernatant was discarded after each cen-
trifugation, leaving approximately 0.5 ml of suspension. 
0.4 ml of acetic acid/methanol (5:3) solution was added to 
the culture 10 min later. The cells were centrifuged again 
and 5 ml of methanol was added. After a further centrifu-
gation, the cell suspension was twice fixed in a methanol/
acetic acid solution (7:1) and then centrifuged again. The 
tubes were then placed in a freezer for two hours. The pel-
let was resuspended and 3 drops were placed on a clean 
slide kept at -20°C. The slides were stained with Giemsa 
solution. Afterwards, they were washed with distilled wa-
ter and left to dry overnight.
For each sample, 1000 binucleated cells were scored un-
der optical microscope for MN analysis, following the 
criteria for determining MN [26]. We evaluated MN fre-
quency as the number of micronucleated cells per 1000 
cells (‰). To avoid differences between observers, the 
same individual carried out the microscopic analyses.
The Nuclear Division Index (NDI), a cell proliferation 
index, was calculated by scoring mono-, bi-, tri- and 
tetranucleated cells in accordance with Eastmond and 
Tucker [27].
Statistical analysis. All analyses were performed using 
SPSS 18.0 (Chicago, USA). Continuous variables were 
expressed as mean ± standard deviation (SD), whereas 
categorical variables were expressed in absolute and per-
centage values.
For continuous variables, differences between groups 
were compared by the Mann-Whitney test and 1-way 
Analysis of Variance (ANOVA), where applicable. Ho-
mogeneity of variance was evaluated using the Levene 
test. ANOVA was performed with a Brown-Forsythe 
adjustment for heteroscedasticity, and with a post-hoc 
Tukey test or Dunnett’s T3 procedure for multiple com-
parisons of unequal variances in order to determine 
which groups differ from the others. 
Pearson’s chi-square and the likelihood ratio chi-square 
were used for proportions. 
Univariate and multivariate logistic regression analyses 
were performed to examine predictors of abnormal MN 
frequency. Variables that proved to be associated with 
higher MN frequency (p < 0.25) in univariate analyses 
were inserted in a multivariate logistic regression model 
in order to investigate independent predictors of high 
frequency. Stepwise regression analysis was performed 
in order to select the variables adopted in the multivari-
ate model. For all analyses, a p-value of < 0.05 was con-
sidered to be statistically significant.
Results
The demographic characteristics and risk factors of CRF 
patients and healthy controls are shown in Table I. The 
average age of the control group was lower (53.2 ± 10.2) 
than that of patients treated by BD (57.0 ± 12.0) and 
HDF (59.8 ± 10.1), although the differences were not 
statistically significant. The differences between patients 
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Tab. I. Characteristics of patients with bicarbonate hemodialysis (group 1), hemodiafiltration (group 2), and control group.
Group 1  
(n = 20)
Group 2 
(n = 20)
p-value
Control Group  
(n = 40)
p-value
Age (± Sd) 57.0 ± 12.0 59.8 ± 10.1 0.685* 53.2 ± 10.2 0.075**
gender, male, n (%) 12 (60.0) 13 (65.0) 0.774^ 27 (64.7) 0.623^^
risk factors
diagnostic test
    radiography, n (%) 18 (90.0) 16 (80.0) 0.661^ 38 (95.0) 0.074
    CAT, n (%) 12 (60.0) 11 (55.0) 0.927^ 7 (17.5) 0.749^^
    Scintigraphy, n (%) 17 (85.0) 13 (65.0) 0.273^ 1 (2.9) 0.000^^
    Angiography, n (%) 4 (20.0) 5 (25.0) 0.519^ 0 (-) 0.001^^
    mammography, n (%) 8 (40.0) 6 (30,0) 0.921^ 3 (8.8) 0.006^^
    radiotherapy, n (%) 0 (-) 0 (-) - 0 (-) -
    mrI, n (%) 0 (-) 1 (5,0) 1.000^ 8 (20.0) 0.235^^
    echography, n (%) 20 (100) 20 (100) 1.000^ 18 (45.0) 1.000^^
Smoke, n (%) 13 (65.0) 6 (30,0) 0.057^ 14 (35.0) 0.025^^
    years of smoking (± Sd) 17.9 ± 7.2 15.5 ± 6.3 0.848* 16.3 ± 10.7 0.829**
Alcohol (all), n (%)
    Wine 15 (78.9) 15 (78.9) 0.715^ 12 (30.0) 0.000^^
    Beer 16 (84.2) 14 (73.7) 0.715^ 12 (30.0) 0.000^^
    Spirits 6 (31.6) 2 (10.5) 0.236^ 7 (17.5) 0.262^^
diabetes, n (%) 3 (15.0) 6 (30.0) 0.449^ 0 (-) 0.000^^
hypertension, n (%) 15 (75.0) 17 (85.0) 0.693^ 5 (12.5) 0.000^^
Intercontinental travel, n (%) 1 (5.0) 1 (6,70) 0.468^ 2 (5.0) 1.000^^
mobile phone repeaters, n (%) 0 (-) 0 (-) - 6 (15.0) 0.012^^
residential area
    Town centre, n (%) 13 (65.0) 13 (65.0) 0.497^ 16 (41.2) 0.001^^
    Suburban, n (%) 3 (15.0) 1 (5.0) 20 (50.0)
    rural area, n (%) 4 (20.0) 6 (30.0) 4 (8.8)
plan home
    ground floor, n (%) 14 (70.0) 16 (80.0) 0.344^ 18 (44.1) 0.016^^
    First floor, n (%) 2 (10.0) 3 (15.0) 17 (42.5)
    Second floor n (%) 4 (20.0) 1 (5.0) 5 (11.8)
education level
    primary school, n (%) 9 (45.0) 6 (30.0) 0.290^ 1 (2.5) 0.000^^
    Secondary school, n (%) 8 (4.0) 16 (30.0) 14 (35.0)
    high school diploma, n (%) 2 (10.0) 6 (30.0) 15 (37.5)
    degree, n (%) 1 (5.0) 2 (10.0) 10 (25.0)
professional exposure
    Ionizing radiation, n (%) 0 (-) 0 (-) - 0 (-) -
    pesticides, n (%) 0 (-) 0 (-) - 0 (-) -
    Chemicals, n (%) 0 (-) 0 (-) - 6 (11.8) 0.012^^
    heavy metals, n (%) 0 (-) 0 (-) - 0 (-) -
    Anesthetic gases, n (%) 7 (35.0) 7 (35.0) 0.740^ 1 (2.9) 0.056^^
    Surgery, n (%) 7 (35.0) 8 (40.0) 1.000^ 13 (32.5) 0.849^^
Kidney transplant, n (%) 4 (20.0) 1 (5.0) 0.442^ 0 (-) -
Time hemodialysis
    ≤ 5 years, n (%) 16 (80.0) 16 (80.0) 0,675^ 0 (-) -
    > 5 years, n (%) 4 (20.0) 4 (20.0) 0 (-)
Frequency hemodialysis
    3 time a week 1 (5.0) 7 (35.0) 0.048^ 0 (-) -
    > 3 time a week 19 (95.0) 13 (65.0) 0 (-)
Kidney failure
    glomerulonephritis, n (%) 8 (40.0) 5 (25.0) 0.399^ 0 (-) -
    Nephroangiosclerosis, n (%) 5 (25.0) 5 (25.0) 0 (-)
    diabetic nephropathy, n (%) 3 (15.0) 7 (35.0) 0 (-)
    Urethral reflux, n (%) 0 (-) 2 (10.0) 0 (-)
    polycystic kidney, n (%) 1 (5.0) 1 (5.0) 0 (-)
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Group 1  
(n = 20)
Group 2 
(n = 20)
p-value
Control Group  
(n = 40)
p-value
    ANCA vasculitis, n (%) 1 (5.0) 0 (-) 0 (-)
    malformation uropathy, n (%) 1 (5.0) 0 (-) 0 (-)
    Chronic rejection, n (%) 1 (5.0) 0 (-) 0 (-)
Legend: Sd, Standard deviation; CAT, Computed Axial Tomography, mrI, magnetic resonance Imaging.
* hSd di Tukey
** ANOvA
^ pearson’s χ2 test 
^^ Likelihood ratio chi-square
Tab. II. Cytogenetic parameters in the studied populations.
Group 1 Group 2 Control Group
N Mean ± SD (median) N Mean ± SD (median)  N Mean ± SD (median) p-value
mN/1,000
    men 12 14.25 ± 9.77 (13.50) 13 13.77 ± 6.76 (14.00) 28 5.88 ± 2.86 (5.00) 0.002*
    Women 8 13.63 ± 5.15 (15.50) 7 23.86 ± 9.25 (23.00) 12 7.67 ± 1.97 (8.00) 0.009*
    Total 20 14.0 ± 8.07 (14.50) 20 17.30 ± 8.96 (15.50) 40 5.88 ± 2.86 (6.00) 0.001*
Time of 
hemodialysis
    ≤ 5 years 16 14.2 ± 8.83 (14.50) 16 18.2 ± 9.52 (18.00) - - - 0.775^
    > 5 years 4 13.2 ± 4.65 (14.00) 4 13.7 ± 5.80 (14.50) - - - 0.725^
p = 0.841^ p = 0.390^
Frequency of 
hemodialysis
    ≤ 3 time a week 19 13.8 ± 8.24 (14.00) 13 18.4 ± 6.33 (20.00) - - - 0.355
    > 3 time a week 1 18.0 (-) 7 15.3 ± 12.91 (9.00) - - - -
p = - p = 0.567^
NdI
    men 12 5.69 ± 4.71 (5.61) 13 4.25 ± 2.98 (4.01) 28 1.14 ± 1.18 (0.58) 0.003*
    Women 8 2.65 ± 2.82 (2.10) 7 4.71 ± 4.48 (3.14) 12 1.39 ± 1.92 (0.57) 0.258*
    Total 20 4.47 ± 4.26 (3.08) 20 4.41 ± 3.47 (3.58) 40 0.94 ± 1.31 (0.58) 0.001*
Legend: Sd, Standard deviation; mN, micronucleus; NdI, Nuclear division Index.
*ANOvA was performed with a Brown-Forsythe adjustment for heteroscedasticity and with dunnett’s T3 procedure for multiple comparisons of unequal 
variances.
^ Test U di mann-Whitney.
Univariate Multivariate
OR (95% CI) p OR (95% CI) p
Age (± Sd) 1.14 (0.51-2.58) 0.742 -
gender, male, n (%) 2.43 (0.65-9.07) 0.183 2.19 (0.14-34.90) 0.577
risk factors
diagnostic test
- radiography, n (%) 1.40 (0.22-8.72) 0.715 -
- CAT, n (%) 2.20 (0.58-8.28) 0.236 7.31 (0.90-59.30) 0.062
- Scintigraphy, n (%) 0.33 (0.08-1.46) 0.139 0.09 (0.01-1.01) 0.051
- Angiography, n (%) 1.27 (0.28-5.68) 0.758 -
- mammography, n (%) 1.89 (0.50-7.09) 0.345 -
Smoke, n (%) 0.51 (0.14-1.85) 0.299 -
Alcohol
- Wine 0.33 (0.08-1.46) 0.139 12.10 (0.00-0.00) 0.997
- Beer, n (%) 0.18 (0.04-0.88) 0.026 0.00 (0.00-0.00) 0.996
- Spirits, n (%) 0.43 (0.07-2.46) 0.321 -
diabetes, n (%) 3.00 (0.69-13.12) 0.139 4.10 (0.38-44.79) 0.247
hypertension, n (%) 1.84 (0.31-10.92) 0.489 -
Tab. III. Univariate and multivariate logistic regression analysis demonstrating the relationship of micronucleus (mN) frequency with most im-
portant experimental variables in dialysis patients.
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on dialysis and controls are linked to the difficulty of re-
cruiting healthy individuals of the same age as patients. 
The risk factor analysis showed no significant difference 
between the two groups of patients undergoing dialysis, 
while highly significant differences emerged among the 
three groups in terms of their exposure to scintigraphy 
(p <  0.000), angiography (p <  0.001), mammography 
(p <  0.006), mobile phone repeaters (p <  0.012) and 
chemicals (p < 0.012), as well as cigarette smoking (p 
< 0.025), wine and beer consumption (both p < 0.000), 
diabetes (p < 0.000), hypertension (p < 0.000), residen-
tial area (p <  0.001), storey of residence (i.e. ground 
floor, first floor, etc.) (p < 0.016) and level of education 
(p < 0.000).
The results of the MN assays on PBL show significantly 
higher frequency in the groups on dialysis than controls 
(p < 0.001), in both males (p < 0.002) and females (p 
< 0.009) (Tab. II). No difference was observed between 
BD and HDF patients and no correlation was observed 
between the number of MN and the duration or weekly 
frequency of treatment. 
In addition, as a measure of cytotoxicity, NDI was found 
to be significantly lower in the control group (p < 0.001) 
than BD and HDF-treated patients. The frequency of 
MN was significantly higher in men (p <  0.003) than 
women (p < 0.258) (Tab. II).
Table III shows the results of the univariate and multi-
variate logistic regression analyses, demonstrating rela-
tionships between MN and other variables. Univariate 
analysis revealed that CAT, scintigraphy, wine and beer 
consumption, diabetes, residence in the suburbs, storey 
of residence, and diabetic nephropathy are significantly 
associated with high MN frequency. However, only CAT 
and scintigraphy independently correlated with high MN 
frequency in a multivariate logistic regression model 
where the variables with p < 0.25 in the univariate anal-
ysis were included as independent variables (Tab. III).
Discussion
Patients with Chronic Kidney Disease (CKD) have a 
higher risk of developing chronic degenerative diseases, 
such as coronary disease, strokes or transient ischemic 
attacks, heart failure, peripheral arterial disease, diabetes 
mellitus, hypertension, dyslipidemia, lung or liver dis-
ease, cancer and dementia [28]. These adverse events are 
associated with severe cytogenetic damage [17].
In this study, damage was assessed by CBMN assay, in 
patients receiving two different dialysis treatments com-
pared with a control group of healthy subjects. CBMN 
is the most frequently used chromosomal biomarker for 
evaluating MN frequency in PBL, which is a good sur-
rogate marker of cancer risk [26].
It is assumed that CRF patients present high levels of 
genetic damage, but very little is known about the ori-
Univariate Multivariate
Intercontinental travel, n (%) 1.53 (0.09-26.43) 0.769 -
Residential area
- Town centre, n (%) 0.83 (0.22-3.12) 0.787 -
- Suburban, n (%) 5.31 (0.50-56.39) 0.134 10.06 (0.27-377.53) 0.212
- Rural area, n (%) 0.56 (0.12-2.60) 0.450 -
Plan home
- Ground floor, n (%) 9.00 (1.01-80.13) 0.016 4.63 (0.14-155.21) 0.392
- First floor, n (%) 0.00 (0.00-0.00) 0.018 0.00 (0.00-0.00) 0.995
- Second floor n (%) 0.33 (0.03-3.30) 0.309 -
Education level
- Primary school, n (%) 1.56 (0.42-5.72) 0.506 -
- Secondary school, n (%) 0.47 (0.12-1.88) 0.273 -
- High school diploma, n (%) 0.88 (0.18-4.32) 0.871 -
- Degree, n (%) 3.29 (0.27-39.66) 0.332 -
Professional exposure
- Anesthetic gases, n (%) 0.76 (0.20-2.90) 0.684 -
- Surgery, n (%) 0.64 (0.17-2.41) 0.502 -
Kidney transplant, n (%) 0.33 (0.03-3.30) 0.309 -
Type of hemodialysis, n (%) 1.52 (0.42-5.43) 0.518
Time hemodialysis 0.43 (0.07-2.46) 0.321 -
Frequency hemodialysis 0.88 (0.18-4.32) 0.871 -
Kidney failure
- Glomerulonephritis, n (%) 0.56 (0.14-2.26) 0.404 -
- Nephroangiosclerosis, n (%) 1.73 (0.41-7.33) 0.459 -
- Diabetic nephropathy, n (%) 3.00 (0.69-13.12) 0.139 4.10 (0.37-44.79) 0.247
- Urethral reflux, n (%) 1.53 (0.09-26.43) 0.769 -
Legend: OR, Odds Ratio; SD, Standard Deviation; CAT, Computed Axial Tomography, MRI, Magnetic Resonance Imaging.
Variables showing a tendency of association with abnormal MN frequency (p < 0.25) in the univariate analysis were included in the multivariate model.
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gins of this damage. Patients at all stages of CRF have 
greater oxidative stress than healthy people but it is even 
more severe in patients undergoing haemodialysis [29]. 
The problem of oxidative stress in patients on dialysis 
is mainly related to the accumulation of uraemic tox-
ins and other endogenous substances with genotoxic 
properties  [30]. The impairment of DNA damage re-
pair is essentially caused by increased production of 
ROS [31-33]. CKD (which leads to the accumulation 
of metabolites) and haemodialysis (which removes me-
tabolites) are among the factors associated with DNA 
damage [34].
Several studies, using a variety of techniques for the de-
tection of chromosomal damage, have shown higher lev-
els of genetic damage in CFR patients than controls [7, 
8]. This was confirmed in the current study, in which 
a statistical difference in MN frequency between CFR 
patients and healthy volunteers was observed. 
The degree of chromosome damage seems to be influ-
enced by both the stage of CKD and the dialysis tech-
nique used [19, 22], although studies show some disa-
greement regarding the latter. Indeed some studies show 
a smaller degree of DNA damage in HD than BD, while 
others evince the opposite [35, 36]. Our study found no 
significant difference in oxidative damage between pa-
tients receiving HD and BD.
Factors such as age, gender, tobacco and alcohol intake, 
diabetes, hypertension and level of education were not 
found to influence the genotoxic effect of haemodialysis 
treatment.
The univariate and multivariate logistic regression anal-
yses showed that the risk factors associated with higher 
DNA damage are diagnostic procedures involving expo-
sure to ionizing radiation (CAT and scintigraphy). Lit-
erature data suggest that exposure to ionizing radiation 
induces the formation of MN and increases the risk of 
cancer and cardiovascular diseases [37, 38]. 
Some authors have shown that DNA damage correlates 
with the duration of dialysis treatment after more than 7 
years [18, 22].
The results of this study show no relationship between 
genetic instability and the type and frequency of haemo-
dialysis. In terms of the duration of treatment, the aver-
age for the BD and HDF patients was respectively 3.8 ± 
6.3 and 3.7 ± 3.9 yrs, not sufficient to assess its relation-
ship with genetic instability.
Our results are consistent with the findings of Kan E et 
al., in which the average duration of dialysis treatment 
was approximately 3.5 years [39]. Another limitation of 
our study is the small sample size, which is not sufficient 
to distinguish between the DNA damage induced by the 
different treatments. Therefore, in order to expand this 
study, a larger number of patients, in treatment for more 
than 10 years, is required.
In conclusion, the results of the research provide evi-
dence that patients undergoing dialysis show a higher 
frequency of nuclear anomalies, resulting in alterations 
of genetic material as well as failures in repair mecha-
nisms. Both CRF and the dialysis used to treat it can con-
tribute to chromosomal and/or genomic damage, bearing 
in mind that the formation of MN mainly originates from 
acentric chromosome fragments or whole chromosomes 
secluded from daughter nuclei during mitosis.
The severe DNA damage in CRF patients, exacerbated 
by the dialysis used to treat the condition, is relevant to 
the debate about possible intervention strategies to re-
duce the risk of cancer and cardiovascular disease. The 
use of highly biocompatible membranes, ultrapure di-
alysates and extracorporeal removal of ROS, as well 
as the many dietary antioxidants and pharmacological 
agents now being used to modulate the levels of genetic 
damage, need to be further investigated.
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